Christina Yau

Nov 6, 2024 | cell.com | Michael Campbell |Denise Wolf |Christina Yau |Lamorna Brown-Swigart |Isela R. Gallagher |Zelos Zhu | +20 more

ResultsA total of 69 HER2− patients (40 HR+HER2− and 29 TN) were randomized to receive 4 cycles of pembrolizumab in combination with weekly paclitaxel followed by anthracycline chemotherapy (Pembro+T → AC). In addition, there were 181 HER2− patients (96 HR+HER2− and 85 TN) randomized to the standard neoadjuvant chemotherapy control group (T → AC). We utilized three assay platforms to characterize the tumor immune microenvironment in these patients (Figure 1).

Jun 14, 2023 | jamanetwork.com | Rita A. Mukhtar |Christina Yau |Laura Esserman

In Reply We thank O’Keefe and Wallace for reading our study.1 In our analysis of data from I-SPY2, a prospective, randomized, neoadjuvant trial with prespecified pathological assessment of specimens according to the Residual Cancer Burden method, we found a nonsignificant difference in 3-year event-free survival (EFS) and distant recurrence-free survival (DRFS) among those with pathologic complete response (pCR) with or without residual ductal carcinoma in situ (DCIS).